ASH 2020 | What is on the CAR-T horizon?
Chiara Magnani
• 11 Dec 2020
Chiara Magnani, MD, Tettamanti Research Center, University of Milano-Bicocca, Monza, Italy, shares her thoughts on the developments we might see in the CAR-T and cellular therapy field in the coming years. She discusses how CAR-T products could be improved, including through using multi-targeting approaches and novel non-viral manufacturing methods. The use of off-the-shelf cellular therapies and increased evaluation of CAR-T products in solid tumors is also likely to be seen in the near future. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
